Cardiac Versus Renal Response to Volume Expansion in Preclinical Systolic Dysfunction With PDEV Inhibition and BNP

Siu Hin Wan, Isabel Torres-Courchoud, Paul M. McKie, Joshua P. Slusser, Margaret M. Redfield, John C. Burnett, David O. Hodge, Horng H. Chen

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Impaired cardiorenal response to acute saline volume expansion in preclinical systolic dysfunction (PSD) may lead to symptomatic heart failure. The objective was to determine if combination phosphodiesterase-V inhibition and exogenous B-type natriuretic peptide (BNP) administration may enhance cardiorenal response. A randomized double-blinded, placebo-controlled study was conducted in 21 subjects with PSD and renal dysfunction. Pre-treatment with tadalafil and subcutaneous BNP resulted in improved cardiac function, as evidenced by improvement in ejection fraction, left atrial volume index, and left ventricular end-diastolic volume. However, there was reduced renal response with reduction in renal plasma flow, glomerular filtration rate, and urine flow. (Tadalafil and Nesiritide as Therapy in Pre-clinical Heart Failure; NCT01544998)

Original languageEnglish (US)
Pages (from-to)962-972
Number of pages11
JournalJACC: Basic to Translational Science
Volume4
Issue number8
DOIs
StatePublished - Dec 2019

Keywords

  • B-type natriuretic peptide
  • cardiorenal
  • heart failure
  • nesiritide
  • phosphodiesterase inhibition
  • systolic dysfunction

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Cardiac Versus Renal Response to Volume Expansion in Preclinical Systolic Dysfunction With PDEV Inhibition and BNP'. Together they form a unique fingerprint.

  • Cite this